Abstract: The present disclosure relates to a method for preparing a haemostatic composition comprising thrombin, the method comprising the step of reconstituting a dry thrombin directly in a paste, such as a paste comprising a biocompatible polymer. The haemostatic composition comprising thrombin may be prepared from a dry thrombin composition and a paste in a single step operation and be used for treatment of a wound.

Abstract: A stick-shaped cosmetic product including (a) 0.1 to 4 mass % of at least one selected from a partially cross-linked polyether modified silicone and a partially cross-linked polyglycerin modified silicone, (b) 1 to 10 mass % of wax, and (c) 30 mass % or more of an aqueous component.

Abstract: Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.

Abstract: Provided are combinations comprising terbinafine or a pharmaceutically acceptable salt thereof and a NO source. The combination may be a synergistic combination. Also provided are methods of treating and/or preventing a fungal infection in a subject comprising administering terbinafine or a pharmaceutically acceptable salt thereof to the subject; and administering a NO source to the subject, thereby treating and/or preventing the fungal infection in the subject. The dose of terbinafine or a pharmaceutically acceptable salt thereof and the dose of the NO source administered to the subject may achieve a synergistic effect.

Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

Abstract: The need for a fast acting and broad spectrum antimicrobial composition which does not reduce surface shine and does not leave visible residues on the surface, while also providing greater residuality of the actives can be met by formulating antimicrobial compositions as described herein.

Abstract: Methods for forming a polyelectrolyte complex (PEC) film are provided. In embodiments, the method comprises applying a potential between a working electrode and a counter electrode, the electrodes in contact with an aqueous polyelectrolyte solution characterized by a bulk pH. The aqueous polyelectrolyte solution comprises a pH sensitive PEC pair comprising an unmodified anionic polymer and a cationic species, an electrochemical pH agent other than water, and a salt. The applied potential induces an electrochemical reaction of the electrochemical pH agent to generate OH? or H+ at the working electrode without inducing water electrolysis in the aqueous polyelectrolyte solution, thereby forming a PEC film from the unmodified anionic polymer and the cationic species on a surface of the working electrode.

Abstract: A sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation. In this sterile composition, the structure and function (activity) of the protein are retained.

Abstract: The present invention provides a method for making an adhesive composition. An adhesive substrate comprising at least a first cyanoacrylate monomer is provided and then mixed with a thickening agent containing polycyanoacrylate prepared by polymerization of a second cyanoacrylate monomer initiated with an aqueous solution of ammonium hydroxide or alcohol. In light of low boiling point of ammonium hydroxide and alcohol, they can be easily removed by heating at low temperature. As such, conventional premature polymerization of adhesive substrate owing to addition of a thickening agent containing residual accelerators can be overall improved.

Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).

Abstract: The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.

Abstract: A donor capable of controlled release of nitric monoxide and a prosthetic implant whose surface is coated with this donor are disclosed. The donor comprises a main chain of an organic polymer and a side chain that is covalently linked to the main chain and has a diazeniumdiolate functional group. The donor for controlled release of nitric monoxide exists in a fluid state such as liquid at room temperature and undergoes a sol-to-gel phase transition at a physiological pH as the temperature increases above the critical temperature. The critical temperature of the phase transition is in the range of 25 to 35° C., and the gel is a hydrogel without chemical cross-links.

Abstract: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.

Abstract: Surgical procedures of the breast where an adhesive is applied to fixate a reshaped and/or relocated portion of breast tissue.

Abstract: Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed.

Abstract: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.

Abstract: Disclosed is a novel means by which plant diseases can be controlled. The antibacterial agent for a phytopathogenic bacterium/bacteria and the agent for plant disease control according to the present invention comprise as an effective ingredient cyanoacrylate polymer particles having an average particle diameter of less than 1000 nm, which particles contain at least one selected from the group consisting of amino acids, amino acid derivatives, and oligomers and polymers thereof, and substantially do not contain an active antibacterial ingredient effective against a phytopathogenic bacterium/bacteria. The agents according to the present invention have no risk of toxicity to humans, livestock, fishes and birds, as well as have a lower impact on the environment. Since this novel antibacterial agent is completely different from existing antibiotics, the agent can be used even in the case where a drug-resistant strain has emerged.

Abstract: The present invention utilizes a combination of a porous carrier and an adsorbent such as a molecular sieve to make a more effective hemostatic device to treat wounds in mammalian animals. These hemostatic devices contain additives that do not inhibit hemostasis.

Abstract: A cosmetic product comprising a polymer having recurring units of formula (1): wherein R1 is independently an alkyl group or a fluorinated alkyl group having 1 to 12 carbon atoms, R2 is methyl group or hydrogen atom, R3 is a divalent saturated hydrocarbon group having 1 to 6 carbon atoms, letter a is an integer of 1 to 3, and X is a monovalent group represented by formula (i): wherein R4 is independently an alkyl group or a fluorinated alkyl group having 1 to 12 carbon atoms and letter b is an integer of 1 to 5.

Abstract: A pH-responsive cell scaffold for growing a cell culture is disclosed. The cell scaffold has pores in which biological cells may be disposed. As the pH of the local environment drops, the cell scaffold swells to draw in additional oxygen and/or other nutrients. The increased supply of oxygen and/or nutrients increases the longevity of the cells. In some embodiments, the cell scaffold induces a change in gene expression that promotes wound healing.

Abstract: The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions.

Abstract: Guanidine-based poly (amidoamine) polymers of formula (I): wherein n is an integer between 3 and 400; R1 is H, C1-6 alkyl; or taken together with the N atoms to which is bound and R2 is a piperazinic ring; R2 is C2-6 alkylen; C5-6 cycloalkylen; CH—COOH, CH—COOR, wherein R is C1-4 alkyl, phenyl or benzyl; R3 is —(CH2)p-HN—C(NH2)?NH, wherein p is an integer 1 to 6; for use as antiviral agents in the prevention and/or treatment of viral infections in a mammal, preferably a human subject.

Abstract: The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.

Abstract: Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.

Abstract: The present application relates to oligomeric antimicrobial compounds and compositions comprising the same. The oligomers are formed by polymerizing aminoalkyl(meth)acrylate or aminoalkyl(meth)acrylamide monomer(s). In addition to imparting materials with broad spectrum antimicrobial activity, the oligomers can impart antimicrobial activity to substrates such as hair and skin.

Abstract: The invention relates to the field of polymers and olefin polymerization, and more specifically olefin metathesis polymerization. The invention provides regioregular alternating polymers and methods of synthesizing such polymers.

Abstract: The present invention relates to controlled release systems that may be administered other than intravenously. The controlled release system is directed to active ingredients, entrapped in or otherwise incorporated in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the active ingredients are covalently bonded to the polymer carriers or polymeric devices. The controlled release systems may suitably be used to treat diseases.

Abstract: A composition which can be detached from a surface which composition serves the purpose of impeding the detrimental effects of adherent fouling from the environment surrounding the surface. The composition may be single layered or multilayered as to allow for removal or attachment at multiple time points and/or over different durations. These time points may correspond to a progression to a negative effect of fouling, such as progression from biofilm maturation to bacterial detachment into host tissue for indwelling medical devices, or a predetermined threshold of tolerable fouling effect, such as blockage of a foley catheter by organic and inorganic encrustation material. This composition does not contribute to the function of the surface or the object whose boundaries are defined by the surface, such that its attachment or detachment is primarily aimed at mitigating the effects of fouling.

Abstract: The present invention provides an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing composition, not only having low toxicity, low harmfulness and high adhesive strength but also being excellent in workability during application and being capable of forming films of excellent properties. The compound of the present invention is comprised a monomer (A), polymer particles (B) having a specific weight-average molecular weight and a specific volume mean particle diameter, and a polymerization initiator composition (C) containing an organoboron compound is produced.

Abstract: The present disclosure is directed to a class of fluorinated copolymers, such as a PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.

Abstract: The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Abstract: Disclosed is a novel means by which cyanoacrylate polymer particles still more useful as an antibacterial agent, an anticancer agent, etc., than conventional particles. The method for production of cyanoacrylate polymer particles according to the present invention comprises anionically polymerizing a cyanoacrylate monomer(s) in the presence of at least one selected from the group consisting of amino acids, amino acid derivatives, and oligomers and polymers thereof, and substantially in the absence of a saccharide and substantially in the absence of a polysorbate. Cyanoacrylate nanoparticles containing an amino-based molecule(s) exhibit their cell-damaging activity via specific adhesion to cells, and effectively inhibit the growth of cancer cells and bacteria. Their cell-damaging activity can be further increased by producing the nanoparticles by the above-mentioned novel production method.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Abstract: The present invention concerns molecularly imprinted polymers (MIPs) having an affinity for natriuretic peptides, such as atrial natriuretic peptide (ANP). In some embodiments, the MIP is a nanoparticle (a molecularly imprinted polymeric nanoparticle (MIPNP)). Other aspects of the invention include methods of preparing an MIP having affinity for a natriuretic peptide, methods for binding a natriuretic peptide in vitro or in vivo using an MIP of the invention, methods for interfering with the binding of a natriuretic peptide with its receptor in vivo, methods for reducing inflammation, cell growth, cell differentiation, or a cell proliferation disorder, methods for detecting natriuretic peptides, and devices and kits for sequestering and/or detecting natriuretic peptides.

Abstract: The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions.

Abstract: The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.

Abstract: A cosmetic product comprising a polymer having recurring units of formula (1): wherein R1 is independently an alkyl group or a fluorinated alkyl group having 1 to 12 carbon atoms, R2 is methyl group or hydrogen atom, R3 is a divalent saturated hydrocarbon group having 1 to 6 carbon atoms, letter a is an integer of 1 to 3, and X is a monovalent group represented by formula (i): wherein R4 is independently an alkyl group or a fluorinated alkyl group having 1 to 12 carbon atoms and letter b is an integer of 1 to 5.

Abstract: The invention is directed to a copolymer comprising at least three types of monomeric units, said three types of monomeric units comprising: a temperature-sensitive unit, a hydrophilic unit, and a hydrophobic unit comprising at least one pH-sensitive moiety; wherein said hydrophobic monomeric unit is derived from a copolymerizable unsaturated fatty acid.

Abstract: Guanidine-based poly (amidoamine) polymers of formula (I): wherein n is an integer between 3 and 400; R1 is H, C1-6 alkyl; or taken together with the N atoms to which is bound and R2 is a piperazinic ring; R2 is C2-6 alkylen; C5-6 cycloalkylen; CH—COOH, CH—COOR, wherein R is C1-4 alkyl, phenyl or benzyl; R3 is —(CH2)p-HN—C (NH2)?NH, wherein p is an integer 1 to 6; for use as antiviral agents in the prevention and/or treatment of viral infections in a mammal, preferably a human subject.

Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.

Abstract: The present invention provides an allergen inhibitor which effectively prevents allergens from reacting with specific antibodies, mitigates the allergic symptoms or prevents appearance thereof, and is less likely to cause unpredictable discoloration and discoloration under usual conditions. The allergen inhibitor of the present invention comprises an allergen-inhibiting compound including a linear polymer having at least one of substituents represented by the formulas (1) to (3) at a side chain. Thus, the allergen inhibitor of the present invention shows excellent allergen-inhibiting effects.

Abstract: An improved viscoelastic composition useful in the performance of ophthalmic surgical procedures and especially cataract procedures is disclosed. The embodiments of the composition comprise combinations of sodium hyaluronate and chondroitin sulfate and exhibit an improved rheological profile.

Abstract: The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

Abstract: [Problem] To provide an antibacterial agent which can be limited to the required location on the surface of a material without mixing and has excellent antibacterial, antifungal and antiviral effects even at low concentrations of the active component without elution or volatilization. [Solution] An antibacterial agent that contains as an active component a resin having an organic group represented by general formula (I-1). (In the formula (I-1), R1 and R2 mutually independently represent a C1-C4 fluoroalkyl group. “C” and “A” are bonded to each other through a covalent bond or an ionic bond, and “A” represents a hydrogen atom or a cation.

Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.

Abstract: A biological coating material that includes a polymerizable polyacrylate monomer; a volatile liquid; a polymer selected from a synthetic rubber, a natural rubber, and a thermoplastic elastomer. The biological liquid coating material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin of a user inhibits the application surface from adhering to another surface.

Abstract: Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers.